Sanofi and CD&R sign Opella share purchase agreementParis, February 19, 2025. Following completion of the required social and corporate ...

Execution of a share buyback agreement for up to €2 billion Paris, February 7, 2025. On January 30, 2025 (https://www.sanofi.com/en/media-room/press-releases/2025/ ...

In 2024, Sanofi (NASDAQ:SNY) worked hard to become primarily a biopharma company, which included selling a dominant stake in Opella, a major company in the over-the-counter and vitamins ...

OpenAI’s big rebranding effort brings a new logo and a new typeface, OpenAI sans. OpenAI’s big rebranding effort brings a new logo and a new typeface, OpenAI sans. Emma Roth is a news writer ...

L’Oreal OR-1.27%decrease; red down pointing triangle will sell part of its stake in Sanofi SAN-0.21%decrease; red down pointing triangle back to the French pharmaceutical company for 3 billion ...

In October 2024, Sanofi entered talks with US private equity company Clayton Dubilier & Rice (CD&R) over the sale of Opella, valued at around $17bn. A deal is slated to be completed by Q2 this year.

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...

Sanofi is in the process of transitioning into a pure vaccine and drug manufacturer as the company edges closer to closing a deal that would see it sell a controlling stake in its consumer health ...

In 2025, Sanofi will receive a cash consideration in the high single-digits in billions in euros from the Opella transaction at the earliest in Q2 while retaining a significant stake in the ...

A €5 billion share buyback program is planned for 2025, aiming to offset Opella dilution and enhance ... potentially impacting market share. Sanofi delivered robust Q4 2024 results with strong ...

Sanofi (NASDAQ: SNY) Q4 2024 Earnings Call Jan 30, 2025, 9:00 a.m. ET Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. Contents: Prepared Remarks ...